Medincell S.A.

Medincell S.A. is a pioneering biopharmaceutical company that focuses on the development of innovative and sustainable long-acting injectable therapies. With a mission to improve global health, Medincell specializes in creating treatments that extend the release of medications over weeks or months, thereby improving patient adherence and outcomes. The company's proprietary technology, BEPO®, serves as a versatile platform for various applications, enabling consistent delivery of pharmaceuticals in fields such as psychiatry, pain management, and reproductive health. Headquartered in Jacou, France, Medincell collaborates with pharmaceutical companies and non-profit organizations worldwide to address unmet medical needs. By reducing the frequency of dosing requirements, Medincell’s solutions aim to enhance the convenience and efficacy of treatments, marking a significant contribution to the healthcare industry. Its focus on sustainable and patient-centric solutions grants Medincell a vital role in advancing medical treatments, particularly in therapeutic areas requiring long-term management.